6.
Wong R, Cheung R, Ahmed A
. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology. 2013; 59(6):2188-95.
DOI: 10.1002/hep.26986.
View
7.
Castera L, Friedrich-Rust M, Loomba R
. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019; 156(5):1264-1281.e4.
PMC: 7505052.
DOI: 10.1053/j.gastro.2018.12.036.
View
8.
Mikolasevic I, Orlic L, Franjic N, Hauser G, Stimac D, Milic S
. Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?. World J Gastroenterol. 2016; 22(32):7236-51.
PMC: 4997649.
DOI: 10.3748/wjg.v22.i32.7236.
View
9.
Keirsse J, Lahaye E, Bouter A, Dupont V, Boussard-Pledel C, Bureau B
. Mapping bacterial surface population physiology in real-time: infrared spectroscopy of Proteus mirabilis swarm colonies. Appl Spectrosc. 2006; 60(6):584-91.
DOI: 10.1366/000370206777670558.
View
10.
Anne M, Le Lan C, Monbet V, Boussard-Pledel C, Ropert M, Sire O
. Fiber evanescent wave spectroscopy using the mid-infrared provides useful fingerprints for metabolic profiling in humans. J Biomed Opt. 2009; 14(5):054033.
DOI: 10.1117/1.3253319.
View
11.
Newsome P, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V
. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2020; 384(12):1113-1124.
DOI: 10.1056/NEJMoa2028395.
View
12.
Francque S, Bedossa P, Ratziu V, Anstee Q, Bugianesi E, Sanyal A
. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. N Engl J Med. 2021; 385(17):1547-1558.
DOI: 10.1056/NEJMoa2036205.
View
13.
Harrison S, Bashir M, Guy C, Zhou R, Moylan C, Frias J
. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019; 394(10213):2012-2024.
DOI: 10.1016/S0140-6736(19)32517-6.
View
14.
Jirapinyo P, McCarty T, Dolan R, Shah R, Thompson C
. Effect of Endoscopic Bariatric and Metabolic Therapies on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2021; 20(3):511-524.e1.
DOI: 10.1016/j.cgh.2021.03.017.
View
15.
Ishikawa M, Maekawa K, Saito K, Senoo Y, Urata M, Murayama M
. Plasma and serum lipidomics of healthy white adults shows characteristic profiles by subjects' gender and age. PLoS One. 2014; 9(3):e91806.
PMC: 3954792.
DOI: 10.1371/journal.pone.0091806.
View
16.
Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than T
. Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. Hepatology. 2019; 70(4):1457-1469.
PMC: 6766425.
DOI: 10.1002/hep.30626.
View
17.
Long M, Pedley A, Massaro J, Hoffmann U, Ma J, Loomba R
. A simple clinical model predicts incident hepatic steatosis in a community-based cohort: The Framingham Heart Study. Liver Int. 2018; 38(8):1495-1503.
PMC: 6206437.
DOI: 10.1111/liv.13709.
View
18.
Lee C, Kim J, Han J, Oh D, Kim M, Jeong H
. Formyl peptide receptor 2 determines sex-specific differences in the progression of nonalcoholic fatty liver disease and steatohepatitis. Nat Commun. 2022; 13(1):578.
PMC: 8803937.
DOI: 10.1038/s41467-022-28138-6.
View
19.
Jena P, Sheng L, Liu H, Kalanetra K, Mirsoian A, Murphy W
. Western Diet-Induced Dysbiosis in Farnesoid X Receptor Knockout Mice Causes Persistent Hepatic Inflammation after Antibiotic Treatment. Am J Pathol. 2017; 187(8):1800-1813.
PMC: 5530909.
DOI: 10.1016/j.ajpath.2017.04.019.
View
20.
Smati S, Polizzi A, Fougerat A, Ellero-Simatos S, Blum Y, Lippi Y
. Integrative study of diet-induced mouse models of NAFLD identifies PPARα as a sexually dimorphic drug target. Gut. 2021; 71(4):807-821.
DOI: 10.1136/gutjnl-2020-323323.
View